Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 28 , ISSUE 2 ( February, 2024 ) > List of Articles


Lurking Danger: Emerging Evidence

Palepu B Gopal

Keywords : Clostridium difficile-associated diarrhea, Fecal microbiota transplantation, Hematopoietic stem cell transplantation

Citation Information : Gopal PB. Lurking Danger: Emerging Evidence. Indian J Crit Care Med 2024; 28 (2):93-94.

DOI: 10.5005/jp-journals-10071-24644

License: CC BY-NC 4.0

Published Online: 30-01-2024

Copyright Statement:  Copyright © 2024; The Author(s).


  1. Kamboj M, Son C, Cantu S, Chemaly RF, Dickman J, Dubberke E, et al. Hospital-onset Clostridium difficile infection rates in persons with cancer or hematopoietic stem cell transplant: A C3IC Network Report. Infect Control Hosp Epidemiol 2012;33(11):1162–1165. DOI: 10.1086/668023.
  2. Ray K. Married to our gut microbiota. Nat Rev Gastroenterol Hepatol 2012;9(10):555. DOI: 10.1038/nrgastro.2012.165.
  3. Quraishi MN, Widlak M, Bhala N, Moore D, Price M, Sharma N, et al. Systematic review with meta-analysis: The efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther 2017;46(5):479–493. DOI: 10.1111/apt.14201.
  4. Moayyedi P, Yuan Y, Baharith H, Ford AC. Faecal microbiota transplantation for Clostridium difficile-associated diarrhoea: A systematic review of randomised controlled trials. Med J Austral 2017;207(4):166–172. DOI: 10.5694/mja17.00295.
  5. Thakur A, Acharya S, Shukla S. Faecal microbiota transplant: A new biologic frontier in medicine. J Clin of Diagn Res 2023;17(5):OE01–OE04. DOI: 10.7860/JCDR/2023/59214/17737.
  6. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. New Engl J Med 2013;368(5):407–415. DOI: 10.1056/NEJMoa1205037.
  7. Choi HH, Cho YS. Fecal Microbiota Transplantation: Current applications, effectiveness, and future perspectives. Clin Endosc 2016;49(3):257–265. DOI: 10.5946/ce.2015.117.
  8. Merrick B, Allen L, Masirah M Zain N, Forbes B, Shawcross DL, Goldenberg SD. Regulation, risk and safety of faecal microbiota transplant. Infect Prevent Pract 2020;2(3):100069. DOI: 10.1016/j.infpip.2020.100069.
  9. Soman R, Sunavala A. Clostridium_difficile_infection-_is_it_coming_at_us. JAPI 2012;60:9–10. PMID: 23767195.
  10. Barbut F, Jones G, Eckert C. Epidemiology and control of Clostridium difficile infections in healthcare settings. Curr Opin Infect Dis 2011;24(4):370–376. DOI: 10.1097/QCO.0b013e32834748e5.
  11. Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital-onset, healthcare facility-associated clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 2011;32(4):387–390. DOI: 10.1086/659156.
  12. Khanna S, Pardi DS. Clostridium difficile infection: New insights into management. Mayo Clin Proc 2012;87(11):1106–1117. DOI: 10.1016/j.mayocp.2012.07.016.
  13. Prayag PS, Patwardhan SA, Ajapuje PS, Melinkeri S, Gadhikar H, Palnitkar S, et al. Fecal Microbiota Transplantation for Clostridium difficile-associated diarrhea in hematopoietic stem cell transplant recipients: A single-center experience from a tertiary center in India. Indian J Crit Care Med 2024;28(2):106–110.
  14. Arbel LT, Hsu E, McNally K. Cost-effectiveness of fecal microbiota transplantation in the treatment of recurrent clostridium difficile infection: A literature review. Cureus 2017;9(8):e1599. DOI: 10.7759/cureus.1599.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.